Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Biofrontera is raising $3,683,209.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Erica Monaco played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Biofrontera
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company develops and markets innovative products for the care, protection and treatment of the skin. The companys lead product is the combination of Ameluz, a topical prescription drug, and medical device BF-RhodoLED for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz has been marketed in the EU since 2012 and in the United States since May 2016. In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin.

To learn more about Biofrontera, visit http://www.biofrontera-us.com/

Contact:
Erica Monaco, Chief Executive Officer
781-245-1325
https://www.linkedin.com/in/erica-l-monaco-cpa-a9b07a7/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved